Olof Eriksson1, Kirsi Mikkola2, Daniel Espes3, Lauri Tuominen4, Kirsi Virtanen2, Sarita Forsbäck2, Merja Haaparanta-Solin2, Jarmo Hietala4, Olof Solin5, Pirjo Nuutila6. 1. Turku PET Centre, University of Turku, Turku, Finland Department of Biosciences, Åbo Akademi University, Turku, Finland olof.eriksson@pet.medchem.uu.se. 2. Turku PET Centre, University of Turku, Turku, Finland. 3. Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 4. Turku PET Centre, University of Turku, Turku, Finland Department of Psychiatry, University of Turku, Turku, Finland. 5. Turku PET Centre, University of Turku, Turku, Finland Accelerator Laboratory, Åbo Akademi University, Turku, Finland; and. 6. Turku PET Centre, University of Turku, Turku, Finland Department of Endocrinology, Turku University Hospital, Turku, Finland.
Abstract
UNLABELLED: Recently, the existence of significant deposits of brown adipose tissue (BAT) in human adults was confirmed. Its role in the human metabolism is unknown but could be substantial. Inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonabant (SR141716) has been associated with activation of BAT thermogenesis and weight loss in mice and rats. The role of peripheral and central CB1 in the activation of BAT merits further investigation. Here we developed a technique for quantifying CB1 in BAT by PET. METHODS: Sections of rat BAT and subcutaneous white adipose tissue (WAT) were stained for CB1 and uncoupling protein-1 by immunofluorescent staining. Binding of the radiolabeled CB1 antagonist (3R,5R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)-phenyl)pyrrolidin-2-one ((18)F-FMPEP-d2) to BAT in vivo and in vitro was assessed in rats by PET. RESULTS: We found that CB1 was colocalized with uncoupling protein-1 in BAT, but neither protein was found in WAT. Binding of the radiotracer to BAT sections (but not WAT) in vitro was high and displaceable by pretreatment with rimonabant. Deposits of BAT in rats had significant binding of (18)F-FMPEP-d2 in vivo, indicating high CB1 density. WAT deposits were negative for (18)F-FMPEP-d2, consistent with the immunofluorescent staining and in vitro results. CONCLUSION: (18)F-FMPEP-d2 PET can quantify CB1 density noninvasively in vivo in rats. CB1 is therefore a promising surrogate imaging biomarker for assessing the presence of BAT deposits as well as for elucidating the mechanism of CB1 antagonist-mediated weight loss.
UNLABELLED: Recently, the existence of significant deposits of brown adipose tissue (BAT) in human adults was confirmed. Its role in the human metabolism is unknown but could be substantial. Inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonabant (SR141716) has been associated with activation of BAT thermogenesis and weight loss in mice and rats. The role of peripheral and central CB1 in the activation of BAT merits further investigation. Here we developed a technique for quantifying CB1 in BAT by PET. METHODS: Sections of rat BAT and subcutaneous white adipose tissue (WAT) were stained for CB1 and uncoupling protein-1 by immunofluorescent staining. Binding of the radiolabeled CB1 antagonist (3R,5R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)-phenyl)pyrrolidin-2-one ((18)F-FMPEP-d2) to BAT in vivo and in vitro was assessed in rats by PET. RESULTS: We found that CB1 was colocalized with uncoupling protein-1 in BAT, but neither protein was found in WAT. Binding of the radiotracer to BAT sections (but not WAT) in vitro was high and displaceable by pretreatment with rimonabant. Deposits of BAT in rats had significant binding of (18)F-FMPEP-d2 in vivo, indicating high CB1 density. WAT deposits were negative for (18)F-FMPEP-d2, consistent with the immunofluorescent staining and in vitro results. CONCLUSION: (18)F-FMPEP-d2 PET can quantify CB1 density noninvasively in vivo in rats. CB1 is therefore a promising surrogate imaging biomarker for assessing the presence of BAT deposits as well as for elucidating the mechanism of CB1 antagonist-mediated weight loss.
Authors: Ran Cheng; Masayuki Fujinaga; Jing Yang; Jian Rong; Ahmed Haider; Daisuke Ogasawara; Richard S Van; Tuo Shao; Zhen Chen; Xiaofei Zhang; Erick R Calderon Leon; Yiding Zhang; Wakana Mori; Katsushi Kumata; Tomoteru Yamasaki; Lin Xie; Shaofa Sun; Lu Wang; Chongzhao Ran; Yihan Shao; Benjamin Cravatt; Lee Josephson; Ming-Rong Zhang; Steven H Liang Journal: Acta Pharmacol Sin Date: 2022-05-05 Impact factor: 6.150
Authors: Chongzhao Ran; Daniel S Albrecht; Miriam A Bredella; Jing Yang; Jian Yang; Steven H Liang; Aaron M Cypess; Marco L Loggia; Nazem Atassi; Anna Moore Journal: Mol Imaging Biol Date: 2018-04 Impact factor: 3.488
Authors: Lu Hou; Jian Rong; Ahmed Haider; Daisuke Ogasawara; Cassis Varlow; Michael A Schafroth; Linjing Mu; Jiefeng Gan; Hao Xu; Christopher J Fowler; Ming-Rong Zhang; Neil Vasdev; Simon Ametamey; Benjamin F Cravatt; Lu Wang; Steven H Liang Journal: J Med Chem Date: 2020-12-30 Impact factor: 7.446
Authors: André C Carpentier; Denis P Blondin; Kirsi A Virtanen; Denis Richard; François Haman; Éric E Turcotte Journal: Front Endocrinol (Lausanne) Date: 2018-08-07 Impact factor: 5.555
Authors: S V Hartimath; S Khanapur; R Boominathan; L Jiang; P Cheng; F F Yong; P W Tan; E G Robins; J L Goggi Journal: Mol Metab Date: 2019-05-06 Impact factor: 7.422